JW Life Science said that Baxter Pharmaceutical, its European partner, has launched Finomel, a ready-to-use triple-chamber bag for parenteral nutrition (PN), in EU.
|JW Life Science's parenteral nutrition solution Finomel|
Finomel is a third-generation nutrient solution that ideally combines omega-3 and omega-6, which promote patient recovery, and vitamin E, thus improving immunity. The product also contains the highest omega-3 content among the three-chamber PN products currently sold in the market.
In detail, the product contains four lipid components -- refined fish oil (20 percent), refined soybean oil (30 percent), olive oil (25 percent) and coconut oil (25 percent) -- as well as glucose and amino acids.
“JW, which has been leading the local PN market, has made its first step in Europe through the launch of Finomel,” a company official said. “We will step up our global market penetration based on our production infrastructure and technology.”
Baxter’s Clinical Nutrition Business General Manager Jorge Vasseur also said, “Our investment in new formulations like Finomel demonstrates our commitment to ensure healthcare providers have access to products that address a wide range of nutritional needs, including malnourished patients in the ICU and with other critical illnesses.”
Finomel joins Baxter’s line of industry-leading Olimel PN formulations to strengthen one of the broadest, most complete ready-to-use PN portfolios available to clinicians, Vasseur added.
<© Korea Biomedical Review, All rights reserved.>